Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Radiation Use During Vemurafenib and Cobimetinib Treatment in Patients With BRAFV600 Mutated Stage IV or Unresectable Stage III Melanoma

NCT01843738 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.

NCT NCT01843738
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01843738 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Radiation Use During Vemurafenib and Cobimetinib Treatment in Patients With BRAFV600 Mutated Stage IV or Unresectable Stage III Melanoma
Lead sponsor
University of Utah
Phase
Phase 1
Overall status
Withdrawn
Start date
June 30, 2017
Completion date
August 31, 2022
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brafv600 mutation, stage iv melanoma